Overview

Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Drug-drug interaction (DDI) and Cardiodynamic Evaluation Study To assess the effect of multiple oral doses of edasalonexent on the single-dose pharmacokinetics (PK) of midazolam (a cytochrome P450 [CYP]3A4 sensitive substrate) and of deflazacort (a CYP3A4 moderate sensitive substrate) in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Catabasis Pharmaceuticals
Treatments:
Deflazacort
Midazolam